APIXABAN-FORMULIERUNGEN

European patent · EP3781132 · In force

Register entry

Publication number
EP3781132
Application number
EP19722333
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 15, 2019
Published
Feb 24, 2021
Granted
Mar 20, 2024
Protection ends at the latest
Apr 14, 2039
Next annual fee due
Apr 30, 2027
IPC classes
A61K 9/16 (2006.01)
A61K 31/4545 (2006.01)
A61P 7/02 (2006.01)
Priority
US 201862658175 P 16.04.2018
PCT application
PCT/US2019/027456 15.04.2019
PCT publication
WO2019/204193 24.10.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  4. Dec 25, 2024

    Change

    Published in Swissreg on 25.12.2024

  5. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  6. Mar 26, 2024

    Agent entered

    Representative
    Servopatent GmbH, Bühlstrasse 1, 8125 Zollikerberg

    Published in Swissreg on 26.03.2024

  7. Mar 20, 2024

    Granted

    Published in Swissreg on 20.03.2024

Parties

Holder

Pfizer Inc.

66 Hudson Boulevard East, New York, NY 10001-2192, US

Bristol-Myers Squibb Company

Route 206 & Province Line Road, Princeton, NJ 08543, US

Agent

Servopatent GmbH

Bühlstrasse 1, 8125 Zollikerberg

Inventor

WAYBRANT, Brett

Princeton, NJ 08543-4000, US

STEVENS, Timothy, D.

Princeton, NJ 08543-4000, US

BADAWY, Sherif, Ibrahim, Farag

Princeton, NJ 08543-4000, US

KUNTZ, Daniel

Princeton, NJ 08543-4000, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.